Top 100 Contractors in PSC 6505: Drugs and Biologicals, FY2022

Parent companies by net contract obligations Oct 1, 2021 – Sep 30, 2022 Code page on GovTribe

The top 10 won 90% of FY2022 PSC 6505 contract dollars

Ranking facts

Contract obligations
$40,718,726,583 Net of deobligations, by contracts coded PSC 6505
Contractors
505 Parent companies with an obligation
Largest contractor
Pfizer Inc. $18 billion, 41.1% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $18,008,581,649
Rank history: #1 in FY2021, #4 in FY2023, not on the FY2024 list and #61 in FY2025; unchanged since FY2021.
2 $11,669,417,226
Rank history: #2 in FY2021, #1 in FY2023, #1 in FY2024 and #1 in FY2025; unchanged since FY2021.
3 $2,752,650,080
Rank history: #6 in FY2021 and not on the FY2023–FY2025 lists; up 3 since FY2021.
4
Modernatx Inc. 2 awardees, including Moderna US, Inc.
$1,847,427,026
Rank history: #3 in FY2021 and not on the FY2023–FY2025 lists; down 1 since FY2021.
5 $1,629,157,855
Rank history: #8 in FY2021, #45 in FY2023, #11 in FY2024 and #18 in FY2025; up 3 since FY2021.
6 $1,490,844,526
Rank history: #5 in FY2021, #3 in FY2023, #2 in FY2024 and #2 in FY2025; down 1 since FY2021.
7 $997,153,496
Rank history: #7 in FY2021, #14 in FY2023 and not on the FY2024–FY2025 lists; unchanged since FY2021.
8
Amerisourcebergen Corporation Through Amerisourcebergen Drug Corp
$321,089,675
Rank history: not on the FY2021 list, #2 in FY2023, #3 in FY2024 and not on the FY2025 list; new.
9 $293,125,000
Rank history: #13 in FY2021, #8 in FY2023, #6 in FY2024 and #5 in FY2025; up 4 since FY2021.
10 $250,768,991
Rank history: #10 in FY2021, #5 in FY2023, #5 in FY2024 and #3 in FY2025; unchanged since FY2021.
11 $139,777,304
Rank history: not on the FY2021 list, #99 in FY2023, not on the FY2024 list and #7 in FY2025; new.
12
Hamilton Bonaduz AG Through Hamilton Company
$128,162,528
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
13 $126,904,912
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
14 $118,928,428
Rank history: not on the FY2021 list, #16 in FY2023, not on the FY2024 list and #12 in FY2025; up 131 since FY2021.
15 $108,720,203
Rank history: #14 in FY2021, #23 in FY2023 and not on the FY2024–FY2025 lists; down 1 since FY2021.
16 $101,544,582
Rank history: #16 in FY2021, #7 in FY2023 and not on the FY2024–FY2025 lists; unchanged since FY2021.
17 $92,861,984
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
18 $83,980,000
Rank history: #20 in FY2021, #9 in FY2023, #9 in FY2024 and #8 in FY2025; up 2 since FY2021.
19 $79,869,432
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
20 $72,141,704
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
21 $59,026,988
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
22 $48,247,223
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 99 since FY2021.
23 $38,202,456
Rank history: #21 in FY2021, #10 in FY2023, #20 in FY2024 and #28 in FY2025; down 2 since FY2021.
24
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$35,215,784
Rank history: #22 in FY2021, #12 in FY2023, #40 in FY2024 and not on the FY2025 list; down 2 since FY2021.
25 $31,291,020
Rank history: not on the FY2021 list, not on the FY2023 list, #16 in FY2024 and not on the FY2025 list; new.
26 $30,867,660
Rank history: #19 in FY2021 and not on the FY2023–FY2025 lists; down 7 since FY2021.
27 $29,364,649
Rank history: #31 in FY2021, #13 in FY2023, #17 in FY2024 and #17 in FY2025; up 4 since FY2021.
28 $26,677,764
Rank history: #18 in FY2021, #27 in FY2023, #22 in FY2024 and not on the FY2025 list; down 10 since FY2021.
29 $22,898,798
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
30 $22,266,060
Rank history: #28 in FY2021, #19 in FY2023, #29 in FY2024 and not on the FY2025 list; down 2 since FY2021.
31 $17,164,194
Rank history: #27 in FY2021, #69 in FY2023, not on the FY2024 list and #68 in FY2025; down 4 since FY2021.
32 $17,002,505
Rank history: #32 in FY2021, #24 in FY2023 and not on the FY2024–FY2025 lists; unchanged since FY2021.
33 $13,724,650
Rank history: #41 in FY2021, #20 in FY2023, #28 in FY2024 and #22 in FY2025; up 8 since FY2021.
34 $12,790,000
Rank history: #36 in FY2021, #28 in FY2023 and not on the FY2024–FY2025 lists; up 2 since FY2021.
35 $12,619,832
Rank history: not on the FY2021 list, #37 in FY2023, #34 in FY2024 and not on the FY2025 list; new.
36 $12,318,053
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
37 $12,054,711
Rank history: #34 in FY2021 and not on the FY2023–FY2025 lists; down 3 since FY2021.
38 $12,038,892
Rank history: not on the FY2021 list, #17 in FY2023, #19 in FY2024 and #16 in FY2025; up 95 since FY2021.
39 $9,895,824
Rank history: #46 in FY2021, not on the FY2023 list, #62 in FY2024 and #67 in FY2025; up 7 since FY2021.
40 $8,227,212
Rank history: #23 in FY2021 and not on the FY2023–FY2025 lists; down 17 since FY2021.
41
Dakco Distributors Inc. Through Dakota Drug, Inc.
$8,102,418
Rank history: #40 in FY2021, #30 in FY2023, #35 in FY2024 and not on the FY2025 list; down 1 since FY2021.
42 $7,792,792
Rank history: #94 in FY2021, #29 in FY2023, #36 in FY2024 and not on the FY2025 list; up 52 since FY2021.
43 $7,385,763
Rank history: #43 in FY2021, not on the FY2023 list, #30 in FY2024 and #93 in FY2025; unchanged since FY2021.
44
Zoll Medical Corporation 2 awardees, including Veloxis Pharmaceuticals, Inc.
$7,374,334
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
45 $7,256,577
Rank history: #54 in FY2021, #15 in FY2023, #51 in FY2024 and not on the FY2025 list; up 9 since FY2021.
46 $7,149,881
Rank history: #38 in FY2021, #21 in FY2023, #39 in FY2024 and not on the FY2025 list; down 8 since FY2021.
47 $7,028,908
Rank history: #42 in FY2021, #26 in FY2023, #41 in FY2024 and #46 in FY2025; down 5 since FY2021.
48 $6,739,196
Rank history: #45 in FY2021, #18 in FY2023, #24 in FY2024 and not on the FY2025 list; down 3 since FY2021.
49 $6,457,633
Rank history: #56 in FY2021, #38 in FY2023, #50 in FY2024 and #57 in FY2025; up 7 since FY2021.
50 $6,453,139
Rank history: not on the FY2021 list, not on the FY2023 list, #44 in FY2024 and not on the FY2025 list; new.
51 $4,786,895
Rank history: #37 in FY2021, #47 in FY2023, #53 in FY2024 and #72 in FY2025; down 14 since FY2021.
52 $4,554,429
Rank history: #48 in FY2021, #51 in FY2023, #81 in FY2024 and #83 in FY2025; down 4 since FY2021.
53 $3,492,273
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #87 in FY2025; new.
54 $3,471,209
Rank history: #60 in FY2021 and not on the FY2023–FY2025 lists; up 6 since FY2021.
55 $3,359,080
Rank history: #58 in FY2021, #40 in FY2023, #47 in FY2024 and #39 in FY2025; up 3 since FY2021.
56 $3,134,479
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 76 since FY2021.
57 $3,022,104
Rank history: #69 in FY2021, #54 in FY2023 and not on the FY2024–FY2025 lists; up 12 since FY2021.
58 $2,994,684
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #32 in FY2025; new.
59 $2,843,987
Rank history: #52 in FY2021, #96 in FY2023, #66 in FY2024 and not on the FY2025 list; down 7 since FY2021.
60 $2,706,640
Rank history: #57 in FY2021, #50 in FY2023, #52 in FY2024 and #47 in FY2025; down 3 since FY2021.
61 $2,693,606
Rank history: not on the FY2021 list, not on the FY2023 list, #76 in FY2024 and #66 in FY2025; new.
62 $2,414,953
Rank history: #67 in FY2021 and not on the FY2023–FY2025 lists; up 5 since FY2021.
63 $2,328,489
Rank history: #50 in FY2021, #42 in FY2023, #48 in FY2024 and not on the FY2025 list; down 13 since FY2021.
64 $2,315,905
Rank history: #76 in FY2021, #46 in FY2023, #54 in FY2024 and #59 in FY2025; up 12 since FY2021.
65 $2,272,083
Rank history: #86 in FY2021, #44 in FY2023, #83 in FY2024 and #56 in FY2025; up 21 since FY2021.
66 $2,188,838
Rank history: #65 in FY2021 and not on the FY2023–FY2025 lists; down 1 since FY2021.
67 $2,096,964
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 40 since FY2021.
68 $2,093,428
Rank history: #84 in FY2021, #52 in FY2023, #58 in FY2024 and not on the FY2025 list; up 16 since FY2021.
69 $2,085,684
Rank history: #91 in FY2021, #87 in FY2023 and not on the FY2024–FY2025 lists; up 22 since FY2021.
70 $1,974,351
Rank history: #72 in FY2021, #61 in FY2023, #84 in FY2024 and #71 in FY2025; up 2 since FY2021.
71 $1,931,863
Rank history: #51 in FY2021, #31 in FY2023, #49 in FY2024 and not on the FY2025 list; down 20 since FY2021.
72 $1,867,166
Rank history: not on the FY2021 list, #48 in FY2023, #99 in FY2024 and not on the FY2025 list; up 70 since FY2021.
73 $1,861,670
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 32 since FY2021.
74 $1,804,779
Rank history: #68 in FY2021, #25 in FY2023 and not on the FY2024–FY2025 lists; down 6 since FY2021.
75 $1,753,059
Rank history: #11 in FY2021, #58 in FY2023 and not on the FY2024–FY2025 lists; down 64 since FY2021.
76
Jubilant Life Sciences Limited 2 awardees, including Jubilant Draximage Inc.
$1,734,026
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 44 since FY2021.
77 $1,630,334
Rank history: #49 in FY2021, #57 in FY2023, not on the FY2024 list and #70 in FY2025; down 28 since FY2021.
78 $1,595,780
Rank history: not on the FY2021 list, #73 in FY2023, #88 in FY2024 and #77 in FY2025; up 194 since FY2021.
79 $1,595,319
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
80 $1,571,369
Rank history: #80 in FY2021, #55 in FY2023, #71 in FY2024 and #84 in FY2025; unchanged since FY2021.
81 $1,506,390
Rank history: #66 in FY2021, #59 in FY2023, #75 in FY2024 and #88 in FY2025; down 15 since FY2021.
82
Fresenius Kabi LLC 2 awardees, including Fenwal, Inc.
$1,499,000
Rank history: #64 in FY2021, #22 in FY2023, #42 in FY2024 and not on the FY2025 list; down 18 since FY2021.
83 $1,475,699
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; new.
84 $1,429,010
Rank history: #88 in FY2021, #72 in FY2023, not on the FY2024 list and #76 in FY2025; up 4 since FY2021.
85 $1,425,631
Rank history: #71 in FY2021, #39 in FY2023, #46 in FY2024 and #41 in FY2025; down 14 since FY2021.
86 $1,417,900
Rank history: #62 in FY2021, #98 in FY2023, #64 in FY2024 and not on the FY2025 list; down 24 since FY2021.
87
Stratatech Corporation 2 awardees, including INO Therapeutics LLC and Specgx LLC
$1,400,482
Rank history: #81 in FY2021 and not on the FY2023–FY2025 lists; down 6 since FY2021.
88 $1,333,766
Rank history: not on the FY2021 list, #81 in FY2023, #77 in FY2024 and not on the FY2025 list; up 42 since FY2021.
89 $1,205,791
Rank history: #82 in FY2021, #78 in FY2023, #96 in FY2024 and not on the FY2025 list; down 7 since FY2021.
90 $1,205,368
Rank history: #97 in FY2021, #77 in FY2023, #67 in FY2024 and not on the FY2025 list; up 7 since FY2021.
91 $1,198,134
Rank history: not on the FY2021 list, not on the FY2023 list, #86 in FY2024 and not on the FY2025 list; up 15 since FY2021.
92 $1,183,919
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #91 in FY2025; up 26 since FY2021.
93 $1,165,332
Rank history: #98 in FY2021, #63 in FY2023, #70 in FY2024 and not on the FY2025 list; up 5 since FY2021.
94
Miltenyi Biotec, Inc.
$1,146,514
Rank history: #83 in FY2021 and not on the FY2023–FY2025 lists; down 11 since FY2021.
95 $1,117,630
Rank history: #73 in FY2021, #71 in FY2023, #91 in FY2024 and #45 in FY2025; down 22 since FY2021.
96
Horizon Therapeutics USA Inc.
$1,109,959
Rank history: not on the FY2021 list, #56 in FY2023 and not on the FY2024–FY2025 lists; up 21 since FY2021.
97 $1,098,357
Rank history: not on the FY2021 list, not on the FY2023–FY2024 lists and #82 in FY2025; new.
98 $1,020,804
Rank history: not on the FY2021 list, #92 in FY2023 and not on the FY2024–FY2025 lists; up 75 since FY2021.
99 $1,012,500
Rank history: #61 in FY2021, #49 in FY2023, not on the FY2024 list and #54 in FY2025; down 38 since FY2021.
100
Xellia Pharmaceuticals USA LLC
$1,004,569
Rank history: not on the FY2021 list and not on the FY2023–FY2025 lists; up 312 since FY2021.
Show 75 more

100 of 505 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $43.8 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2022 ran Oct 1, 2021 – Sep 30, 2022. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2021. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2021 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 PSC 6505 contractors in FY2022?

1. Pfizer Inc. ($18B), 2. Mckesson Corporation ($11.7B), 3. ELI Lilly and Company ($2.75B), 4. Modernatx Inc. ($1.85B), 5. Glaxosmithkline LLC ($1.63B), 6. Cencora, Inc. ($1.49B), 7. Merck & Co. Inc. ($997M), 8. Amerisourcebergen Corporation ($321M), 9. Bavarian Nordic A / S ($293M), 10. DMS Pharmaceutical Group Inc. ($251M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work